BioTuesdays
Medical Facilities
Markets

Echelon cuts Medical Facilities PT to $5.50 from $10

Echelon Wealth Partners slashed its price target for Medical Facilities (TSX:DR) to $5.50 from $10 and maintained its “hold” rating after the company reported third quarter results that included a dramatic dividend cut...

November 8, 2019
Allena Pharmaceuticals Logo
Markets

Roth sticking with Allena Pharma despite selloff

Roth Capital Partners believes Allena Pharmaceuticals (NASDAQ:ALNA) is getting “unnecessarily punished” on Nov. 7, despite positive URIROX-1 top-line study data, which included a high placebo response, smaller treatment...

November 7, 2019
Supernus Pharmaceuticals Logo
Markets

Stifel cuts Supernus Pharma to hold; PT to $23 from $55

Stifel downgraded Supernus Pharmaceuticals (NASDAQ:SUPN) to “hold” from “buy” and slashed its price target to $23 from $55 after a Phase 3 miss with drug candidate, SPN-810, for the treatment of impulsive aggression in...

November 7, 2019
Constellation Logo
Markets

HCW ups Constellation Pharma PT to $50 from $18

H.C. Wainwright raised its price target for Constellation Pharmaceuticals (NASDAQ:CNST) to $50 from $18, saying the company’s ASH abstracts lend strong support to a bullish view on CPI-0610’s potential...

November 7, 2019
Markets

SVB Leerink cuts Amneal Pharma to MP; PT to $3 from $4

SVB Leerink downgraded Amneal Pharmaceuticals (NYSE:AMRX) to “market perform” from “outperform” and lowered its price target to $3 from $4 after the company cut its guidance. The stock closed at $2.76 on Nov. 6. Analyst...

November 7, 2019
Hepion Pharmaceuticals
Markets

Roth starts Hepion Pharma at buy; PT $9

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6. “Hepion brings a laser focus on liver disease, combined with...

November 7, 2019
Profound Medical Logo
Markets

Paradigm ups Profound Medical PT to C$45

Paradigm Capital raised its price target for Profound Medical (TSX:PRN; NASDAQ:PROF) to C$45 from C$40 based on the company’s commercialization plan for TULSA-PRO. The stock closed at $12.70 on the TSX on Nov. 5...

November 6, 2019
PDS Biotechnology Logo
Markets

HCW starts PDS Biotechnology at buy; PT $7

H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...

November 5, 2019
Sientra Logo
Markets

WB ups Sientra to OP

William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform,” saying the company’s near-to-midterm outlook has stabilized and is improving. The stock closed at $6.77 on Nov. 4. Analyst Margaret Kaczor writes that she...

November 5, 2019
atyr Pharma
Markets

HCW starts aTyr Pharma at buy; PT $8

H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...

November 5, 2019
Agile Therapeutics
Markets

WB ups Agile Therapeutics to OP

William Blair upgraded Agile Therapeutics (NASDAQ:AGRX) to “outperform” after an FDA advisory committee voted overwhelmingly to approve its resubmitted NDA for the Twirla transdermal combined hormonal contraceptive...

October 31, 2019
Markets

Oyster Point Pharma prices $80-millon IPO

Oyster Point Pharma (NASDAQ:OYST) priced an initial public offering of five million common shares at a price of $16 each to raise gross proceeds of $80-million. The offering is expected to close on Nov. 4. The company...

October 30, 2019
Profound Medical Logo
Markets

Profound Medical to begin trading on NASDAQ

Profound Medical’s (TSX:PRN; OTCQX:PRFMD) common shares have been certified for listing on The Nasdaq Stock Market, with trading slated to begin on Oct. 29 under the stock symbol “PROF.” The company’s common...

October 28, 2019
ekso
Markets

HCW starts Ekso Bionics at buy; PT $1.20

H.C. Wainwright launched coverage of Ekso Bionics Holdings (NASDAQ:EKSO) with a “buy” rating and $1.20 price target. The stock closed at 59 cents on Oct. 25. Ekso Bionics develops and markets robotic exoskeletons for...

October 28, 2019
Stoke Therapeutics
Markets

HCW starts Stoke Therapeutics at buy; PT $30

H.C. Wainwright launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and price target of $30. The stock closed at $22.86. Analyst Debjit Chattopadhyay writes that Stoke is advancing an antisense...

October 25, 2019
Titan Pharmaceuticals Logo
Markets

Maxim ups Titan Pharma to buy with PT of $1

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold,” establishing a $1 price target as the company has raised capital and removed a financing overhang. The stock was quoted at 20 cents in...

October 23, 2019
Senseonics
Markets

Stifel starts Senseonics at buy; PT $2

Stifel initiated coverage of Senseonics Holdings (NYSE American:SENS) with a “buy” rating and $2 price target. The stock closed at 95 cents on Oct. 22. Senseonics is an emerging company with a long-duration, implantable...

October 23, 2019